Decker Wealth Management LLC Makes New $516,000 Investment in Stryker Corporation $SYK

Decker Wealth Management LLC purchased a new position in Stryker Corporation (NYSE:SYK) in the 1st quarter, Holdings Channel reports. The firm purchased 1,570 shares of the medical technology company’s stock, valued at approximately $516,000.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the business. Godfrey Financial Associates Inc. bought a new stake in Stryker in the 4th quarter worth about $26,000. Sankala Group LLC bought a new position in Stryker during the 4th quarter valued at about $26,000. United Financial Planning Group LLC bought a new position in Stryker during the 3rd quarter valued at about $27,000. Atlas Capital Advisors Inc. purchased a new stake in shares of Stryker during the 4th quarter valued at about $27,000. Finally, DJE Kapital AG bought a new stake in shares of Stryker in the fourth quarter worth approximately $28,000. 77.09% of the stock is owned by institutional investors.

Stryker Trading Down 0.0%

Stryker stock opened at $319.78 on Monday. The firm has a 50 day moving average of $312.69 and a 200 day moving average of $336.71. The firm has a market capitalization of $122.59 billion, a price-to-earnings ratio of 37.01, a P/E/G ratio of 2.05 and a beta of 0.77. Stryker Corporation has a 12-month low of $281.00 and a 12-month high of $404.87. The company has a current ratio of 2.11, a quick ratio of 1.25 and a debt-to-equity ratio of 0.62.

Stryker (NYSE:SYK) last issued its quarterly earnings results on Thursday, April 30th. The medical technology company reported $2.60 earnings per share for the quarter, missing the consensus estimate of $2.98 by ($0.38). The firm had revenue of $6.02 billion for the quarter, compared to analysts’ expectations of $6.34 billion. Stryker had a net margin of 13.20% and a return on equity of 23.42%. Stryker’s revenue for the quarter was up 2.6% compared to the same quarter last year. During the same period in the prior year, the firm earned $2.84 EPS. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. As a group, research analysts predict that Stryker Corporation will post 14.99 earnings per share for the current year.

Stryker Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, July 31st. Stockholders of record on Tuesday, June 30th will be given a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a dividend yield of 1.1%. The ex-dividend date is Tuesday, June 30th. Stryker’s dividend payout ratio (DPR) is presently 40.74%.

Insider Activity at Stryker

In related news, VP M Kathryn Fink sold 5,220 shares of Stryker stock in a transaction on Monday, May 11th. The shares were sold at an average price of $283.85, for a total transaction of $1,481,697.00. Following the transaction, the vice president owned 13,137 shares in the company, valued at approximately $3,728,937.45. The trade was a 28.44% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Ronda E. Stryker sold 310,000 shares of the company’s stock in a transaction on Tuesday, May 26th. The stock was sold at an average price of $312.23, for a total transaction of $96,791,300.00. Following the completion of the transaction, the director directly owned 1,924,880 shares of the company’s stock, valued at $601,005,282.40. This represents a 13.87% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders have sold 323,264 shares of company stock worth $100,659,489. 4.60% of the stock is owned by corporate insiders.

Stryker News Roundup

Here are the key news stories impacting Stryker this week:

• Positive Sentiment: Stryker launched Mako RPS, a new handheld robotic power system for total knee replacement, expanding its Mako robotics portfolio beyond robotic-arm assisted surgery and potentially broadening adoption of robotic-assisted orthopedic procedures. Stryker expands Mako robotics portfolio with full market release of Mako RPS
• Positive Sentiment: Media coverage highlighted the full U.S. commercial launch of Mako RPS, reinforcing investor optimism that Stryker is strengthening its competitive position in orthopedic robotics. Stryker fully launches Mako robotic power system for knee surgery in US
• Positive Sentiment: Unusually heavy call-option buying suggested traders were positioning for more upside in SYK, which can sometimes add momentum to the shares.
• Positive Sentiment: RBC Capital reiterated its Buy rating on Stryker, providing another favorable signal from the analyst community. RBC Capital Sticks to Their Buy Rating for Stryker (SYK)
• Neutral Sentiment: MarketWatch noted that Stryker stock outperformed peers on a strong trading day, indicating relative strength but without a specific new company catalyst. Stryker Corp. stock outperforms competitors on strong trading day
• Neutral Sentiment: Analyst commentary on Stryker was mixed in broader healthcare-sector coverage, but no major negative surprise was indicated in the headlines provided. Analysts Offer Insights on Healthcare Companies: Shionogi & Co (OtherSGIOF) and Stryker (SYK)

Analyst Ratings Changes

Several research analysts have recently weighed in on the stock. Wells Fargo & Company decreased their price objective on shares of Stryker from $456.00 to $418.00 and set an “overweight” rating for the company in a report on Friday, May 1st. BTIG Research set a $371.00 target price on shares of Stryker in a report on Monday, July 13th. Deutsche Bank Aktiengesellschaft set a $315.00 target price on shares of Stryker in a research report on Friday, May 1st. Sanford C. Bernstein set a $410.00 target price on shares of Stryker in a research note on Friday, May 1st. Finally, Citigroup lowered their price target on Stryker from $420.00 to $385.00 and set a “buy” rating on the stock in a report on Tuesday, April 7th. One equities research analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and six have issued a Hold rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $392.52.

Stryker Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.